David S. Joseph

David S. Joseph

President & CEO

  • 40+ yrs of experience commercializing medtech/pharma
  • Co-founder of 4 companies with successful exits (IPO, M&A)
  • Multiple past and present board positions
  • Chairman and CEO of Othera Pharmaceuticals (2003‐2010), a specialty pharmaceutical company focused on treatments for ophthalmic diseases
  • Co‐founder, President, CEO and Chairman of Orthovita (1999‐2008), an orthobiologics company (IPO in 2006; acquired by Stryker (NYSE:SYK) in 2012 for US$350 million)
  • Co‐founder, President, CEO and Chairman of Surgical Laser Technologies (IPO in 1989; acquired by Photo Medix in 1992)
  • Co‐founder, President, CEO and Chairman of SITE Microsurgical Systems (acquired by Johnson & Johnson Corporation (NYSE:JNJ) in 1983)
  • Prior to entrepreneurial career, over 15 years of executive healthcare management experience
  • Past and present board appointments include two successful acquisitions: Animas Corporation, a diabetes insulin pump technology acquired by Johnson & Johnson for approximately US$515 million in 2006; Morphotek, a privately held biotechnology company acquired by Eisai Pharmaceuticals for approximately US$325 million in 2007; and Allevi, a 3D Bioprinting company
  • MBA in Healthcare Administration degree from Xavier University
  • BA in Business Administration from Kings College
G. Michael Landis

Richard Murray, MD

Chief Medical Officer

  • 25+ years industry experience
  • Executive at Merck & Co. for many years in commercial, medical and scientific areas, most recently as Vice President and Deputy Chief Patient Officer
  • Management experience in all areas of Medical Affairs, including outcomes research, medical information, academic and professional affairs, field-based medical physicians, and investigator-initiated trials globally
  • Fellow at the Advanced Leadership Initiative at Harvard University
  • Previously a practicing physician in pulmonary medicine and an asthma researcher at the Hospital of the University of Pennsylvania
Graham Timmins

Graham Timmins, PhD

Chief Science Advisor

  • Assoc. Professor of Med. Chemistry at UNM
  • Co-inventor of the Company’s patent portfolio
  • Author/co-author of >50 publications; awarded several federal grants

Subscribe to receive our press releases

Stock Info:
CSE:   AVBT $0.00